Characteristic | n (%) |
---|---|
Age, median (range) | 69 (46–87) |
Pts (lesion) | 18 (25) |
Sex | |
 Male  Female | 9 (50%) 9 (50%) |
Primitive site of tumor | |
 Colorectal cancer  Gynecologist cancer (ovary, uterine)  Hepatocellular carcinoma  Others | 4 (23,1%) 8 (42,30%) 2 (7,7%) 4 (26,9%) |
Irradiated metastatic Lesion reSBRTÂ =Â 25 | |
 Liver  Perihepatic abdominal carcinosis | 20(80%) 5(20%) |
Timing between I and re-SBRT, months, mean (range) | 8,5 (2–28) |
Oligometastatic disease classification | |
 Metachronous oligorecurrence  Metachronous oligoprogression  Induced oligo persistence | 4 (22,2%) 12 (66,6%) 2 (11,2%) |
Gating treatment for lesion | |
Breath hold inspiration Free breathing | 18(70%) 7 (30%) |
PTV volume (cm3), mean (range) | 13,3 (3,6–34,9) |
PTV Dose I SBRT liver, median dose (range), mean BED α/β10 | 43,1 (24–50), 95 |
PTV Dose reSBRT liver, median dose (range), mean BED α/β10 | 41,3 Gy (16–50), 93 |
Liver dose reSBRT (Gy), mean dose (range), mean EQD2 | 3,7 Gy (1,6–8 Gy), 3 |
Mean Follow up, months (range) | 11 (3–34) |
Toxicity at the mean Follow up | |
 GI Grade 0–1  GI Grade 2 | 0 0 |